Compare MCO & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | VRTX |
|---|---|---|
| Founded | 1900 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4B | 135.6B |
| IPO Year | 1998 | 2007 |
| Metric | MCO | VRTX |
|---|---|---|
| Price | $466.78 | $515.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 32 |
| Target Price | $553.67 | ★ $595.36 |
| AVG Volume (30 Days) | 765.2K | ★ 1.3M |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | 21.40 | ★ 836.54 |
| EPS | ★ 12.98 | 10.90 |
| Revenue | ★ $4,204,100,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.50 | $10.46 |
| Revenue Next Year | $6.70 | $10.53 |
| P/E Ratio | ★ $36.35 | $47.77 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $402.28 | $412.27 |
| 52 Week High | $546.88 | $568.67 |
| Indicator | MCO | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 41.75 |
| Support Level | $460.33 | $493.75 |
| Resistance Level | $476.73 | $536.58 |
| Average True Range (ATR) | 12.25 | 15.90 |
| MACD | -5.50 | -3.73 |
| Stochastic Oscillator | 3.58 | 4.74 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).